Evolution in the management of vestibular schwannoma: a single-center 15-year experience.
Abstract
[PURPOSE] To highlight the changes in the management of vestibular schwannoma (VS) since 2004 with a focus on small- to middle-size VS.
[METHODS] Retrospective analysis of the decisions made in skull base tumor board between 2004 and 2021.
[RESULTS] 1819 decisions were analyzed (average age 59.25, 54% females). Overall, 850 (47%) cases were allocated to a Wait and Scan (WS) approach, 416 (23%) received radiotherapy and 553 (30%) were treated surgically (MS). All stages considered WS increased from 39% before 2010 to 50% after 2010. Similarly, Stereotactic Radio Therapy (SRT) increased from 5 to 18%. MS decreased from 46 to 25%. It was more commonly proposed to younger patients and larger tumors, p < 0.001. For Koos stages 1, 2, and 3 there was a statistically significant increase in SRT, and a decrease in MS, p < 0.001. WS also increased for stages 1 and 2. However, such a trend was not observed for stage 3. MS remained the primary treatment modality for stage 4 tumors throughout the study period, p = 0.057. The significance of advanced age as a factor favoring SRT decreased over time. The opposite is true for serviceable hearing. There was also a decrease in the percentage of the justification "young age" in the MS category.
[CONCLUSION] The is a continuing trend towards non-surgical treatment. Small- to medium-sized VS witnessed an increase in both WS and SRT. There is only an increase in SRT for moderately large VS. Physicians are less and less considering young age as a factor favoring MS over SRT. There is a tendency towards favoring SRT when hearing is serviceable.
[METHODS] Retrospective analysis of the decisions made in skull base tumor board between 2004 and 2021.
[RESULTS] 1819 decisions were analyzed (average age 59.25, 54% females). Overall, 850 (47%) cases were allocated to a Wait and Scan (WS) approach, 416 (23%) received radiotherapy and 553 (30%) were treated surgically (MS). All stages considered WS increased from 39% before 2010 to 50% after 2010. Similarly, Stereotactic Radio Therapy (SRT) increased from 5 to 18%. MS decreased from 46 to 25%. It was more commonly proposed to younger patients and larger tumors, p < 0.001. For Koos stages 1, 2, and 3 there was a statistically significant increase in SRT, and a decrease in MS, p < 0.001. WS also increased for stages 1 and 2. However, such a trend was not observed for stage 3. MS remained the primary treatment modality for stage 4 tumors throughout the study period, p = 0.057. The significance of advanced age as a factor favoring SRT decreased over time. The opposite is true for serviceable hearing. There was also a decrease in the percentage of the justification "young age" in the MS category.
[CONCLUSION] The is a continuing trend towards non-surgical treatment. Small- to medium-sized VS witnessed an increase in both WS and SRT. There is only an increase in SRT for moderately large VS. Physicians are less and less considering young age as a factor favoring MS over SRT. There is a tendency towards favoring SRT when hearing is serviceable.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 합병증 | vestibular schwannoma
|
scispacy | 1 | ||
| 약물 | [RESULTS] 1819
|
scispacy | 1 | ||
| 약물 | SRT
→ Stereotactic Radio Therapy
|
scispacy | 1 | ||
| 질환 | vestibular schwannoma
|
C0027859
Acoustic Neuroma
|
scispacy | 1 | |
| 질환 | tumor
|
C0027651
Neoplasms
|
scispacy | 1 | |
| 질환 | tumors
|
C0027651
Neoplasms
|
scispacy | 1 | |
| 질환 | serviceable hearing
|
scispacy | 1 | ||
| 질환 | hearing is serviceable
|
scispacy | 1 | ||
| 질환 | skull base tumor
|
scispacy | 1 | ||
| 기타 | Koos stages 1, 2
|
scispacy | 1 |
MeSH Terms
Female; Humans; Middle Aged; Male; Neuroma, Acoustic; Retrospective Studies; Treatment Outcome; Hearing; Dose Fractionation, Radiation; Follow-Up Studies